IRulya Therapeutics — Third Quarter 2026 Earnings Summary

IRulya Therapeutics Inc., formerly Quince Therapeutics, reported a net loss of $27.7 million for the third quarter ended September 30, 2026, while maintaining a cash position of $105.2 million expected to fund operations through 2028. The company relaunched with a new name and ticker symbol IRLA, appointing a new leadership team and board of directors to focus on its lead candidate, LAM-001. Clinical progress includes a fully enrolled Phase 2 trial for bronchiolitis obliterans syndrome (BOS) with data anticipated in early 2027, an ongoing Phase 2b trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD), and a planned Phase 2 study for sarcoidosis-associated pulmonary hypertension (SAPH) to begin in late 2026.